Generalized Myasthenia Gravis Pipeline

Key Takeaways

• Novel therapeutic agents for gMG target specific disease pathways, potentially improving efficacy and safety over traditional treatments.
• Complement inhibitors and FcRn antagonists are among the promising emerging treatments for gMG.
• These advancements may enhance patient outcomes, reduce disease burden, and offer personalized treatment options.